Barbara Dalton

Title
Head, Pfizer Ventures
Company
Pfizer
Bio
At Pfizer Barbara is responsible for Pfizer Venture Investments, as well as oversight for equity based transactions that support out-licensing, in-licensing, research collaborations and incubator activity. Barbara has spent over 20 years in the Pharmaceutical industry - most of that time as a corporate venture capitalist. She began her career as a research scientist and pursued anti-inflammatory drug discovery research at SmithKline and French Research Laboratories for ten years. She joined SmithKline’s venture capital group, S.R. One, Limited in the early 1990’s. While there Barbara was a founding member of EuclidSR Partners, a private New York based venture capital firm where SmithKline (now GSK) was a leading limited partner. She joined that firm full time in 2003. In 2007 she moved to her current position at Pfizer with responsibility for growing their corporate venture activities. As a venture capitalist Barbara has had management responsibility for over 25 indirect fund investments and 100 diverse direct company investments throughout the world, but primarily in the US. She has had managed investments in companies pursuing drug development and platform technologies, healthcare IT, as well as some healthcare service businesses. Her funds have invested in companies such as: Ablexis, Adolor, Alere, Amgen, Avalon, Avid, Aquinox, British Biotechnology, CAT, Celladon, Cephalon, Clovis, Corixa, DVS, Fluidym, Genset, HandyLab, IDEC, Inhale, Kosan, Kudos, Leukosite, Lexicon, Memory, Merus, NTP, Neuronetics, Nodality, NovoCure, OGS, Ribi, Rib-X, Scynexis, Sepracor, Targacept, Tetralogix, TWT and Versecor. While managing individual investments Barbara has a seat at the Board, either as a member or an observer. As a board member she participates on subcommittees of the board that focus on Compensation, Audit or M&A. She currently represents Pfizer’s Investments in Ablexis, Accelerator NYC, Cydan, Ixchelsis, Levicept, NexImmune, and Rhythm Pharmaceuticals. In the community she has been active in her regional venture investors association, the MAC Alliance, serving as a past Chairman. She was also a board member of the Institute for the Study of Ageing, the NY Biotechnology Association, and the National Venture Capital Association where she chaired the Corporate Venture Capital subgroup. She Chairs the Healthcare Subcommittee of the New York City Investment Fund. At Penn State, Barbara is an advisor to the Dean of the Eberly College of Scienc, and a member of The Penn State Research Foundation Board of Directors.